Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Enzon Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Enzon Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
Enzon Pharmaceuticals's earnings are expected to grow by 6.7% yearly, however this is not considered high growth (20% yearly).
Unable to determine if Enzon Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Enzon Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
3/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Enzon Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Enzon Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Enzon Pharmaceuticals has no long term commitments.
This treemap shows a more detailed breakdown of
Enzon Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Enzon Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Andrew Rackear, J.D., has been the Chief Executive Officer and Secretary of Enzon Pharmaceuticals Inc. since March 31, 2016. Mr. Rackear served as the General Counsel and Secretary of Enzon Pharmaceuticals Inc. since April 2010 until November 30, 2013 and also served as its Vice President and Head of Human Resources. Mr. Rackear served as the Chief Compliance Officer of Enzon Pharmaceuticals since September 2010. Mr. Rackear served as Secretary and General Counsel of APBiotech Inc. Mr. Rackear served as Senior Vice President of Legal Affairs, General Counsel of NPS Pharmaceuticals Inc. from November 15, 2007 to October 30, 2009 and its Secretary from November 2007 to October 30, 2009. Mr. Rackear served as Corporate Secretary of NPS Pharmaceuticals Inc. from November 15, 2007 to October 30, 2009. He joined NPS in July 2007 as its Associate General Counsel and served until November 2007. Previously, he served as Vice President and General Counsel of Chugai Pharma, USA since April 2005. He served as Vice President and General Counsel of Amersham Biosciences Corp. from 2001 to April 2005 and served as its Secretary. He joined Pharmacia Biotech in 1994 as General Counsel and previously served as Counsel of Pharmacia U.S. Inc. from 1993 to 1994. He served as Associate General Counsel of Sharp Electronics Corporation from 1985 to 1988. From 1980 to 1985 and 1988 to 1993, he was in private practice with Marks & Murase in New York City. He is a Member of the New York and New Jersey state bar associations. He holds a BA in History from the University of Rochester and earned his JD at New York University School of Law in 1980.
Andrew's compensation has increased by more than 20% in the past year.
Andrew's remuneration is about average for companies of similar size in Germany.
CEO & Secretary
VP of Finance & CFO
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Enzon Pharmaceuticals board of directors is about average.
Board of Directors
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Enzon Pharmaceuticals insiders in the past 3 months, but not in substantial volumes.
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. Enzon Pharmaceuticals, Inc.was founded in 1981 and is headquartered in Cranford, New Jersey.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.